Cannabinoid research and development leader AXIM® Biotechnologies, Inc. (OTC: AXIM) has announced it’s entering a new clinical trial on treating irritable bowel syndrome (IBS) with its CanChew Plus® CBD chewing gum.
“We are pleased to have reached another milestone in the development of AXIM products to treat challenging health conditions,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech, in a press release. “IBS is the most common functional gastrointestinal disorder affecting 9-23% of the worldwide population, and it has no sustainable cure.”
Known for causing a great deal of discomfort, IBS produces bouts of stomach cramping, bloating, and a change in bowel habits. The global treatment market for IBS is estimated to grow to $1.5 billion by 2023.
The trial will be conducted by the AXIM® Biotech Team and investigators from the world-class education and research institute, Wageningen University. The study will involve 40 patients diagnosed with IBS, ranging in age from 18 to 65. Patients will be treated with controlled-release Hemp oil CBD chewing gum, containing 50mg CBD per serving, and matching placebo gums. The subjects will be allowed to consume up to 6 chewing gums per day and their perceived pain levels, general relief, and change in stool frequency will be recorded.
“IBS is a very common and often painful disorder which is still difficult to manage. People often experience sudden flare-ups and for many it has a negative impact on their quality of life. CBD has shown to have promising effects, but there has been a clear need for practical and effective formulations. Providing it via a chewing gum results in sustained release of the compound and better bio-availability,” said Renger Witkamp, Professor and Chair in Nutrition and Pharmacology of Wageningen University.
AXIM® Biotech’s CanChew Plus® is a unique, hemp-derived CBD chewing gum with a vastly improved delivery system. Just recently, the biotechnology company announced it had received positive pharmacokinetic (PK) data results on its CBD gum, setting the stage for this clinical trial.
“With positive outcomes from the IBS clinical trial, we are ready to proceed immediately with further trials of our pharmaceutical grade CanChew RxTM products to treat inflammatory bowel disease (IBD); Ulcerative colitis and Crohn’s disease. We are committed to finding research based cannabinoid solutions to help people suffering from gastrointestinal disorders and other health conditions with no effective remedies,” said Anastassov.
While the exact cause of IBS has yet to be determined, findings in a recent scientific review indicate that there could be a link between the development of irritable bowel syndrome and clinical endocannabinoid deficit (CED). CED is a condition in which the function of the endocannabinoid system, a system responsible for regulating several functions and maintaining homeostasis, dysfunctions because as a result of the body not generating enough endocannabinoids.
Supplementing the body’s endocannabinoid system with plant-based cannabinoids, like cannabidiol (CBD), could therefore be beneficial in maintaining optimal health and treating the conditions related to cannabinoid deficiency.
AXIM® Biotech published a product pipeline chart in December that highlights the timelines of its upcoming trials. Trials to examine the efficacy of CanChew Plus® on other gastrointestinal disorders are already slated for the coming years. The company secured funding in October for its upcoming clinical trials.